# Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

> **NCT05045508** · PHASE3 · UNKNOWN · sponsor: **Brandon Baartman** · enrollment: 60 (estimated)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** OC-01 (varenicline 0.6mg/ml) nasal spray
- **DRUG:** Placebo (vehicle) Nasal Spray

## Key facts

- **NCT ID:** NCT05045508
- **Lead sponsor:** Brandon Baartman
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-30
- **Primary completion:** 2022-08-30
- **Final completion:** 2023-01-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05045508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05045508, "Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05045508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*